Pfizer Consumer Licenses Antares Delivery Tech

Pfizer’s Consumer Healthcare Business Unit has licensed a drug delivery technology from Antares Pharma to develop an undisclosed product on an exclusive basis for North America. Pfizer will assume full cost and responsibility for all clinical development, manufacturing, and commercialization of the product in the licensed territory, which also includes certain non-exclusive territories outside of North America. Antares will receive undisclosed upfront payments, development milestones and sales based milestones, as well as royalties on net sales for three years after U.S. launch.

“We are very pleased to enter this collaboration with Pfizer Consumer Healthcare for an important product opportunity targeting a growing therapeutic area which utilizes one of our technology platforms,” said Paul K. Wotton, Ph.D., Antares’ president and chief executive officer. “We continue to significantly diversify our existing and future product portfolio through both internal product development programs and Pharma partnerships.”

Antares has partnerships with several other pharma companies, including Teva, Ferring and Watson.